## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## Schedule 14A INFORMATION

Proxy Statement Pursuant to Section 12(a) of the Securities Exchange Act of 1934

	(Amendment No)
	Filed by the Registrant Filed by a party other than the Registrant
Chec	k the appropriate box:
/X/	Preliminary Proxy Statement Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to Rule 14a-11(c) or Rule 14a-12
	Regeneron Pharmaceuticals, Inc.
	(Name of Registrant as Specified In Its Charter)
	Regeneron Pharmaceuticals, Inc.
	(Name of Person(s) Filing Proxy Statement)
Paym	ent of filing Fee (Check the appropriate box):
	No fee required. Fee computed on table below per Exchange Act Rule 14a-6(i)(l) and 0-11.
1)	Title of each class of securities to which transaction applies:
2)	Aggregate number of securities to which transaction applies:
3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
4)	Proposed maximum aggregate value of transaction:
/_/	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Indentify the previous filing by registration statement number, or the form or schedule and the date of its filing.
	1) Amount previously paid:
	2) Form, Schedule, or Registration No.:
	3) Filing party:
	4) Date filed: April 30, 1999

Please date, sign and mail your proxy card back as soon as possible!

Annual Meeting of Shareholders REGENERON PHARMACEUTICALS, INC.

June 11, 1999

A |X| Please mark your votes as in this example

The Board of Directors recommends a vote FOR Items 1, 2, 3, and 4.

or guardian, please give full title as such.

WITHHELD FOR ALL Item 1. Nominees: ELECTION Alfred G. Gilman, M.D., Ph.D. OF Joseph L. Goldstein, M.D. 1\_1 1\_1 DIRECTORS P. Roy Vagelos, M.D. WITHHELD FOR: (Write that nominee's name in the space provided below.) FOR AGAINST ABSTAIN Item 2. Ratify, confirm, and approve the January 22, 1999 resolution of the Board of Directors to increase by 1,500,000 the number of shares reserved for issuance under Regeneron's Amended and Restated 1990 Long-Term Incentive Plan. 1\_1 Item 3. Appointment of PricewaterhouseCoopers LLP as independent accountants. 1\_1 Item 4. In their discretion, upon any other matters as may properly come before the meeting. 1\_1 1\_1 1\_1 Signature: \_\_\_\_\_ Signature: \_\_\_\_ Date: , 1999 Please sign as name appears hereon. Joint owners should each sign. NOTE: When signed as attorney, executor, administrator, trustee,